Geneva, Feb. 2 -- International Clinical Trials Registry received information related to the study (NCT07356245) titled 'Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma' on Jan. 20.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Jonathan Brammer
Condition:
T-cell Lymphoma
Graft Versus Host Disease
Lymphoma, T-Cell
Peripheral T Cell Lymphoma
T-cell Prolymphocytic Leukemia
Cutaneous T Cell Lymphoma
Adult T-cell Leukemia/Lymphoma
Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
Intervention:
Drug: Ruxolitinib
Procedure: Positron emission tomography-computed tomography
Procedure:...